Glofitamab Induces Complete Responses in Relapsed and Refractory Primary Central Nervous System Lymphoma

Although most patients with primary central nervous system lymphoma (PCNSL) respond to treatment with high-dose methotrexate-containing regimens, over 50% relapse and 15% is refractory to treatment. The prognosis of these patients is poor, and limited treatment options exist. This report describes two patients with PCNSL who both progressed after several lines of therapy and who obtained a rapid and complete response after treatment with the bispecific antibody glofitamab. Both tolerated the treatment well without signs of cytokine release syndrome or immune-effector cell-mediated neurotoxicity syndrome. The observed responses highlight that glofitamab is a promising therapeutic option for patients with R/R PCNSL.